We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 35 for:    "Hashimotos syndrome"

Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01102205
Recruitment Status : Completed
First Posted : April 13, 2010
Last Update Posted : June 13, 2013
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Oxidative stress leads to or accompanies with numerous disease. Oxidative balance in subclinical hypothyroid or euthyroid state in Hashimoto disease are not known. Effect of levothyroxine therapy on oxidative balance are also not known in hashimoto disease.

Condition or disease
Hashimoto Disease

Detailed Description:
oxidative stress markers will be measured initially(TAS,TOS,OSI,PARAOXONASE,ARYLESTERASA,PON1 PHENOTYPİNG,LİPİDPEROXİD).After 3 months therapy with levothyroxine measurements will be repeated except PON1 phenotyping.

Study Design

Study Type : Observational
Actual Enrollment : 130 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease
Study Start Date : April 2010
Primary Completion Date : April 2010
Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
healthy
euthyroid hashimoto
hypothyroid hashimoto


Outcome Measures

Primary Outcome Measures :
  1. Poxidative stress markers [ Time Frame: After levotren therapy ]

Biospecimen Retention:   Samples Without DNA
after overnight fasting state,venous blood will be taken to obtain serum.speciemens stored -70 cantigrade celcius untillanalysing.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
adult with Hashimoto disease in euthyroid or subclinical hypothyroid state and healthy control.
Criteria

Inclusion Criteria:

  • age more than 18 years

Exclusion Criteria:

  • inability to give a written consent
  • other conditions and drug usage affect oxidative stress
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01102205


Locations
Turkey
Vakif Gureba Training and Research Hospital
Istanbul, Turkey, 34100
Sponsors and Collaborators
Vakif Gureba Training and Research Hospital
Investigators
Study Chair: Mehmet ali Cikrikcioglu, MD vakif gureba TRH,fatih,istanbul,turkey.specialist in internal medicine
More Information

Responsible Party: Mehmet Ali Cikrikcioglu, Vakif Gureba TRH, Vakif Gureba Training and Research Hospital
ClinicalTrials.gov Identifier: NCT01102205     History of Changes
Other Study ID Numbers: tastoshashi
First Posted: April 13, 2010    Key Record Dates
Last Update Posted: June 13, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Hashimoto Disease
Thyroiditis, Autoimmune
Thyroiditis
Thyroid Diseases
Endocrine System Diseases